CES1 Antibodies, cDNA Clones Research Reagents

CES1 (Carboxylesterase 1, also known as CEH; REH; TGH; ACAT; CES2; HMSE; SES1; HMSE1; PCE-1), located on 16q12.2, is a Protein Coding gene. This gene encodes a member of the carboxylesterase large family. CES1 is the major liver enzyme and functions in liver drug clearance. It is capable of catalyzing the hydrolysis of a wide range of therapeutic agents, toxins, and endogenous compounds. Studies have shown that there is a correlation between the expression and activity of CES1 and the pharmacokinetics and/or pharmacodynamics of CES1 substrate drugs.

CES1 Antibody (1)

    CES1 cDNA Clone (13)

    AB119996.1

    CES1 Background

    CES1 encodes carboxylesterase-1, an important drug-metabolizing enzyme with high expression in the liver. Variants generated by the exchange of segments with CES1P1 complicate the genotyping of CES1. CES1 is involved in the hydrolysis of ester group-containing xenobiotic and endobiotic compounds including several essential and commonly used drugs. The individual variation in the efficacy and tolerability of many drugs metabolized by CES1 is considerable. However, it has been problematic to express recombinant CES1 in bacterial expression systems due to low solubility, with the CES1 protein being mainly expressed in inclusion bodies, accompanied by insufficient purity issues. CES1 is capable of catalyzing the hydrolysis of a wide range of therapeutic agents, toxins, and endogenous compounds. Accumulating studies have demonstrated associations between the expression and activity of CES1 and the pharmacokinetics and/or pharmacodynamics of CES1 substrate medications.

    CES1 References

    • Sanford JC, et al. (2016) Regulatory effects of genomic translocations at the human carboxylesterase-1 (ces1) gene locus. Pharmacogenet Genomics 26 (5): 197-207.
    • Rasmussen HB, et al. (2015) Individualization of treatments with drugs metabolized by ces1: Combining genetics and metabolomics. Pharmacogenomics 16 (6): 649-665.
    • Qian Y, et al. (2020) Natural products as modulators of ces1 activity. Drug Metab Dispos 48 (10): 993-1007.
    • Ferrero-Miliani L, et al. (2017) Reappraisal of the genetic diversity and pharmacogenetic assessment of ces1. Pharmacogenomics 18 (13): 1241-1257.

    Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.